Organon & Co. (OGN)
13.76
+0.01
(+0.07%)
USD |
NYSE |
Oct 20, 16:00
13.76
0.00 (0.00%)
Pre-Market: 20:00
Organon Research and Development Expense (TTM) : 358.00M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 358.00M |
| March 31, 2026 | 363.00M |
| December 31, 2025 | 366.00M |
| September 30, 2025 | 405.00M |
| June 30, 2025 | 432.00M |
| March 31, 2025 | 453.00M |
| December 31, 2024 | 469.00M |
| September 30, 2024 | 473.00M |
| June 30, 2024 | 499.00M |
| March 31, 2024 | 511.00M |
| December 31, 2023 | 528.00M |
| September 30, 2023 | 533.00M |
| Date | Value |
|---|---|
| June 30, 2023 | 523.00M |
| March 31, 2023 | 501.00M |
| December 31, 2022 | 468.00M |
| September 30, 2022 | 518.00M |
| June 30, 2022 | 502.00M |
| March 31, 2022 | 472.00M |
| December 31, 2021 | 443.00M |
| September 30, 2021 | 314.00M |
| June 30, 2021 | 257.00M |
| March 31, 2021 | 232.00M |
| December 31, 2020 | 210.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Merck & Co., Inc. | 27.26B |
| Viatris, Inc. | 995.00M |
| Pfizer Inc. | 10.82B |
| Pacira Biosciences, Inc. | 121.73M |
| Bristol Myers Squibb Co. | 9.548B |